<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578227</url>
  </required_header>
  <id_info>
    <org_study_id>110886</org_study_id>
    <nct_id>NCT00578227</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects</brief_title>
  <official_title>Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) Co-administered With a Commercially Available Vaccine in Healthy Female Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the central cause
      of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and
      thus before exposure to oncogenic HPV, is a rational strategy for prevention of cervical
      cancer, and so HPV vaccination could complement the existing pre-adolescent/adolescent
      vaccination programs. Therefore, this Phase IIIb study is designed to evaluate the safety and
      immunogenicity of co-administering a commercially available vaccine with GSK Biologicals'
      HPV-16/18 L1 AS04 (Cervarix ®) vaccine as compared to the administration of either vaccine
      alone. This Protocol Posting has been updated in order to comply with the FDA AA, Sept 2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies</measure>
    <time_frame>At Month 7</time_frame>
    <description>Seroconversion is defined as the appearance of anti-HAV antibodies [i.e., antibody titer greater than or equal to 15 milli-international units/milliliter (mIU/mL)] in the sera of subjects seronegative (antibody titer below 15 mIU/mL) before vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Heptatis A (HAV) Antibody Titers.</measure>
    <time_frame>At Month 7</time_frame>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed as mIU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroprotected for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies</measure>
    <time_frame>At Month 7</time_frame>
    <description>A subject seroprotected against HBs is a subject with antibody titers greater than or equal to 10 mIU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>At Month 7</time_frame>
    <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values = 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers</measure>
    <time_frame>At Month 7</time_frame>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Antibody Titers</measure>
    <time_frame>At Month 7</time_frame>
    <description>Titers are given as Geometric Mean Titers (GMTs)expressed as mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-HBs Antibodies</measure>
    <time_frame>At month 7</time_frame>
    <description>Seroconversion is defined as the appearance of anti-HBs antibodies (i.e., antibody titer greater than or equal to 3.3 mIU/mL) in the sera of subjects seronegative (with antibody titers below 3.3 mIU/mL) before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Vaccine Recipients Aged 9 Years</measure>
    <time_frame>At Month 7</time_frame>
    <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values = 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers in Vaccine Recipients Aged 9 Years</measure>
    <time_frame>At Month 7</time_frame>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-HAV Antibodies</measure>
    <time_frame>One month after the second dose of vaccine</time_frame>
    <description>Seroconversion is defined as the appearance of anti-HAV antibodies (i.e., antibody titer greater than or equal to 15 mIU/mL) in the sera of subjects seronegative (antibody titer below 15 mIU/mL) before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HAV Antibody Titers</measure>
    <time_frame>One month after the second dose of vaccine</time_frame>
    <description>Titers are given as geometric mean titers (GMTs) expressed as mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted and Number of Subjects Seroprotected for Anti-HBs Antibodies</measure>
    <time_frame>One month after the second dose of vaccine</time_frame>
    <description>Seroconversion is defined as the appearance of anti-HBs antibodies (i.e., antibody titer greater than or equal to 3.3 mIU/mL) in the sera of subjects seronegative (with antibody titers below 3.3 mIU/mL) before vaccination.
A seroprotected subject against HBs is a subject with antibody titers greater than or equal to 10 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Antibody Titers</measure>
    <time_frame>One month after the second dose of vaccine</time_frame>
    <description>Titers are given as geometric mean titers (GMTs) expressed as mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</measure>
    <time_frame>One month after the second dose of vaccine</time_frame>
    <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers</measure>
    <time_frame>One month after the second dose of vaccine</time_frame>
    <description>Titers are given as Geometric Mean Titers (GMTs) expressed as EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>During the 7-day period (Day 0-6) following vaccination</time_frame>
    <description>Solicited local symptoms assessed include injection site pain, redness and swelling. Data are presented across doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms</measure>
    <time_frame>During the 7-day period following vaccination</time_frame>
    <description>Solicited general symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, rash, temperature [axillary route, greater than or equal to 37.5 degree Celsius (°C)] and urticaria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Medically Significant Conditions</measure>
    <time_frame>Throughout the active phase of the study (up to Month 7)</time_frame>
    <description>Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Medically Significant Conditions</measure>
    <time_frame>Throughout the safety follow-up (from Month 7 up to Month 12)</time_frame>
    <description>Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events</measure>
    <time_frame>During the 30-day period following any vaccination</time_frame>
    <description>Unsolicited adverse events include any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>Throughout the study (up to Month 12)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">814</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix™ &amp; Twinrix™ Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix™ Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twinrix™ Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix™</intervention_name>
    <description>Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose</description>
    <arm_group_label>Cervarix™ &amp; Twinrix™ Group</arm_group_label>
    <arm_group_label>Cervarix™ Group</arm_group_label>
    <other_name>HPV vaccine</other_name>
    <other_name>GSK Biologicals' HPV-16/18 L1 AS04</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Twinrix ™ Paediatric</intervention_name>
    <description>Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose</description>
    <arm_group_label>Twinrix™ Group</arm_group_label>
    <arm_group_label>Cervarix™ &amp; Twinrix™ Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their legally acceptable
             representatives (LARs) can and will comply with the requirements of the protocol
             should be enrolled in the study.

          -  A female between, and including, 9 and 15 years of age (has not attained her 16th
             birthday) at the time of the first vaccination.

          -  Written informed consent obtained from the subject prior to enrolment. For subjects
             below the legal age of consent, written informed consent must be obtained from the
             subject's LAR, and written informed assent must be obtained from the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Subjects must not be pregnant.

          -  Subjects must be of non-childbearing potential, or if the subject is of childbearing
             potential, she must be abstinent or use adequate contraception for 30 days prior to
             vaccination and must agree to continue such precautions for two months after
             completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of study vaccine, or planned
             use during the study period (up to Month 12).

          -  Concurrently participating in another clinical study, at any time during the study
             period (up to the Month 12 telephone contact), in which the subject has been or will
             be exposed to an investigational or a non-investigational product (pharmaceutical
             product or device).

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before and 30 days after each dose of vaccine(s). Administration of
             routine vaccines may be allowed up to 8 days before the first dose

          -  A subject planning to become pregnant, likely to become pregnant or planning to
             discontinue contraceptive precautions during the study period and up to two months
             after the last vaccine dose.

          -  Pregnant or breastfeeding women.

          -  Previous vaccination against HPV or planned administration of any HPV vaccine other
             than that foreseen by the study protocol during the study period.

          -  Previous administration of components of the investigational vaccine.

          -  Previous vaccination against hepatitis A or B planned administration of any hepatitis
             A or B vaccine other than that foreseen by the study protocol during the study period.

          -  History of hepatitis A or B infection.

          -  Known exposure to hepatitis A or B within the previous 6 weeks.

          -  Known acute or chronic, clinically significant neurologic, hepatic or renal functional
             abnormality, as determined by previous physical examination or laboratory tests.

          -  Cancer or autoimmune disease under treatment.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 8P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 3T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoersholm</city>
        <zip>2970</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordány</city>
        <zip>6795</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1039</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Győr</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hódmezővásárhely</city>
        <zip>6800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szeged</city>
        <zip>6723</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lycksele</city>
        <zip>SE-921 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-702 11</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlán G, Silfverdal SA, Szüts P, O'Mahony M, David MP, Dobbelaere K, Dubin G, Descamps D. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. J Adolesc Health. 2012 Jan;50(1):38-46. doi: 10.1016/j.jadohealth.2011.10.009.</citation>
    <PMID>22188832</PMID>
  </reference>
  <reference>
    <citation>Pederson C et al. Co-administration of ASO4- adjuvanted human papillomavirus- 16/18 cervical cancer vaccine with inactivated hepatitis A ans B vaccine in girls aged 9-15 years. Abstract presented at the 6th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). Beunos Aires, Argentina, 19-22 November 2009.</citation>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>November 27, 2009</results_first_submitted>
  <results_first_submitted_qc>December 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2010</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human papillomavirus infection,</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>HPV vaccine,</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110886</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110886</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110886</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110886</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110886</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110886</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110886</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although the total number of enrolled subjects for this study was 814, one subject did not receive any study vaccine and was therefore not considered as started in the 'Participant Flow' section.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix™ &amp; Twinrix™ Group</title>
          <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
        </group>
        <group group_id="P2">
          <title>Cervarix™ Group</title>
          <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
        </group>
        <group group_id="P3">
          <title>Twinrix™ Group</title>
          <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="270"/>
                <participants group_id="P3" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="268"/>
                <participants group_id="P3" count="267"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix™ &amp; Twinrix™ Group</title>
          <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
        </group>
        <group group_id="B2">
          <title>Cervarix™ Group</title>
          <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
        </group>
        <group group_id="B3">
          <title>Twinrix™ Group</title>
          <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="272"/>
            <count group_id="B2" value="270"/>
            <count group_id="B3" value="271"/>
            <count group_id="B4" value="813"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="2.04"/>
                    <measurement group_id="B2" value="11.2" spread="2.02"/>
                    <measurement group_id="B3" value="11.2" spread="1.99"/>
                    <measurement group_id="B4" value="11.2" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="271"/>
                    <measurement group_id="B4" value="813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies</title>
        <description>Seroconversion is defined as the appearance of anti-HAV antibodies [i.e., antibody titer greater than or equal to 15 milli-international units/milliliter (mIU/mL)] in the sera of subjects seronegative (antibody titer below 15 mIU/mL) before vaccination.</description>
        <time_frame>At Month 7</time_frame>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, in subjects seronegative for anti-HAV before vaccination (i.e. with antibody titer below 15 mIU/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies</title>
          <description>Seroconversion is defined as the appearance of anti-HAV antibodies [i.e., antibody titer greater than or equal to 15 milli-international units/milliliter (mIU/mL)] in the sera of subjects seronegative (antibody titer below 15 mIU/mL) before vaccination.</description>
          <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, in subjects seronegative for anti-HAV before vaccination (i.e. with antibody titer below 15 mIU/mL).</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Heptatis A (HAV) Antibody Titers.</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed as mIU/mL.</description>
        <time_frame>At Month 7</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for anti-HAV before vaccination (i.e. with antibody titer below 15 mIU/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Heptatis A (HAV) Antibody Titers.</title>
          <description>Titers are given as Geometric Mean Titers (GMTs) expressed as mIU/mL.</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for anti-HAV before vaccination (i.e. with antibody titer below 15 mIU/mL).</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4504.2" lower_limit="3993.0" upper_limit="5080.8"/>
                    <measurement group_id="O3" value="5288.4" lower_limit="4713.3" upper_limit="5933.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroprotected for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies</title>
        <description>A subject seroprotected against HBs is a subject with antibody titers greater than or equal to 10 mIU/mL.</description>
        <time_frame>At Month 7</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for anti-HBs before vaccination, i.e. with anti-HBs antibody titer greater than or equal to 3.3 mIU/mL.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies</title>
          <description>A subject seroprotected against HBs is a subject with antibody titers greater than or equal to 10 mIU/mL.</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for anti-HBs before vaccination, i.e. with anti-HBs antibody titer greater than or equal to 3.3 mIU/mL.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
        <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values = 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
        <time_frame>At Month 7</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
          <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values = 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 (n= 229, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (n= 239, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
        <time_frame>At Month 7</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers</title>
          <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 GMTs (n= 229, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22993.5" lower_limit="20093.4" upper_limit="26312.0"/>
                    <measurement group_id="O2" value="26981.9" lower_limit="23909.5" upper_limit="30449.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 GMTs (n= 239, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8671.2" lower_limit="7651.7" upper_limit="9826.6"/>
                    <measurement group_id="O2" value="11182.7" lower_limit="9924.8" upper_limit="12600.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HBs Antibody Titers</title>
        <description>Titers are given as Geometric Mean Titers (GMTs)expressed as mIU/mL.</description>
        <time_frame>At Month 7</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for anti-HBs before vaccination, i.e. with anti-HBs antibody titers below 3.3 mIU/mL.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HBs Antibody Titers</title>
          <description>Titers are given as Geometric Mean Titers (GMTs)expressed as mIU/mL.</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for anti-HBs before vaccination, i.e. with anti-HBs antibody titers below 3.3 mIU/mL.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3136.5" lower_limit="2436.0" upper_limit="4038.4"/>
                    <measurement group_id="O3" value="5646.5" lower_limit="4481.3" upper_limit="7114.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Anti-HBs Antibodies</title>
        <description>Seroconversion is defined as the appearance of anti-HBs antibodies (i.e., antibody titer greater than or equal to 3.3 mIU/mL) in the sera of subjects seronegative (with antibody titers below 3.3 mIU/mL) before vaccination.</description>
        <time_frame>At month 7</time_frame>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for anti-HBs before vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-HBs Antibodies</title>
          <description>Seroconversion is defined as the appearance of anti-HBs antibodies (i.e., antibody titer greater than or equal to 3.3 mIU/mL) in the sera of subjects seronegative (with antibody titers below 3.3 mIU/mL) before vaccination.</description>
          <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, in subjects seronegative for anti-HBs before vaccination.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Vaccine Recipients Aged 9 Years</title>
        <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values = 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
        <time_frame>At Month 7</time_frame>
        <population>Analysis was performed in 9-year old subjects from the ATP cohort for analysis of immunogenicity, who were seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O4">
            <title>9-Year Old Cervarix Vaccine Recipients</title>
            <description>All 9-year subjects who received 3 doses of HPV vaccine alone or co-administered with HAB vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Vaccine Recipients Aged 9 Years</title>
          <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values = 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
          <population>Analysis was performed in 9-year old subjects from the ATP cohort for analysis of immunogenicity, who were seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 (n= 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (n= 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers in Vaccine Recipients Aged 9 Years</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
        <time_frame>At Month 7</time_frame>
        <population>Analysis was performed in 9-year old subjects from the ATP cohort for analysis of immunogenicity, who were seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O4">
            <title>9-Year Old Cervarix Vaccine Recipients</title>
            <description>All 9-year subjects who received 3 doses of HPV vaccine alone or co-administered with HAB vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers in Vaccine Recipients Aged 9 Years</title>
          <description>Titers are given as Geometric Mean Titers (GMTs) expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).</description>
          <population>Analysis was performed in 9-year old subjects from the ATP cohort for analysis of immunogenicity, who were seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 GMTs (n= 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="32170.2" lower_limit="27985.5" upper_limit="36980.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 GMTs (n= 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="12257.1" lower_limit="10644.6" upper_limit="14113.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Anti-HAV Antibodies</title>
        <description>Seroconversion is defined as the appearance of anti-HAV antibodies (i.e., antibody titer greater than or equal to 15 mIU/mL) in the sera of subjects seronegative (antibody titer below 15 mIU/mL) before vaccination.</description>
        <time_frame>One month after the second dose of vaccine</time_frame>
        <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for anti-HAV before vaccination, i.e. with anti-HAV antibody titers below 15 mIU/mL.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-HAV Antibodies</title>
          <description>Seroconversion is defined as the appearance of anti-HAV antibodies (i.e., antibody titer greater than or equal to 15 mIU/mL) in the sera of subjects seronegative (antibody titer below 15 mIU/mL) before vaccination.</description>
          <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for anti-HAV before vaccination, i.e. with anti-HAV antibody titers below 15 mIU/mL.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HAV Antibody Titers</title>
        <description>Titers are given as geometric mean titers (GMTs) expressed as mIU/mL.</description>
        <time_frame>One month after the second dose of vaccine</time_frame>
        <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for anti-HAV before vaccination, i.e. with anti-HAV antibody titers below 15 mIU/mL.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HAV Antibody Titers</title>
          <description>Titers are given as geometric mean titers (GMTs) expressed as mIU/mL.</description>
          <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for anti-HAV before vaccination, i.e. with anti-HAV antibody titers below 15 mIU/mL.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467.0" lower_limit="374.4" upper_limit="582.5"/>
                    <measurement group_id="O3" value="513.9" lower_limit="418.7" upper_limit="630.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted and Number of Subjects Seroprotected for Anti-HBs Antibodies</title>
        <description>Seroconversion is defined as the appearance of anti-HBs antibodies (i.e., antibody titer greater than or equal to 3.3 mIU/mL) in the sera of subjects seronegative (with antibody titers below 3.3 mIU/mL) before vaccination.
A seroprotected subject against HBs is a subject with antibody titers greater than or equal to 10 mIU/mL.</description>
        <time_frame>One month after the second dose of vaccine</time_frame>
        <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for anti-HBs with antibody titers below 3.3 mIU/mL.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted and Number of Subjects Seroprotected for Anti-HBs Antibodies</title>
          <description>Seroconversion is defined as the appearance of anti-HBs antibodies (i.e., antibody titer greater than or equal to 3.3 mIU/mL) in the sera of subjects seronegative (with antibody titers below 3.3 mIU/mL) before vaccination.
A seroprotected subject against HBs is a subject with antibody titers greater than or equal to 10 mIU/mL.</description>
          <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for anti-HBs with antibody titers below 3.3 mIU/mL.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconverted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HBs Antibody Titers</title>
        <description>Titers are given as geometric mean titers (GMTs) expressed as mIU/mL.</description>
        <time_frame>One month after the second dose of vaccine</time_frame>
        <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for anti-HBs before vaccination, i.e. with antibody titers below 3.3 mIU/mL.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HBs Antibody Titers</title>
          <description>Titers are given as geometric mean titers (GMTs) expressed as mIU/mL.</description>
          <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for anti-HBs before vaccination, i.e. with antibody titers below 3.3 mIU/mL.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" lower_limit="24.9" upper_limit="45.8"/>
                    <measurement group_id="O3" value="43.0" lower_limit="30.1" upper_limit="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
        <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
        <time_frame>One month after the second dose of vaccine</time_frame>
        <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies</title>
          <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies.</description>
          <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 (n=105, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 (n= 112, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers</title>
        <description>Titers are given as Geometric Mean Titers (GMTs) expressed as EL.U/mL.</description>
        <time_frame>One month after the second dose of vaccine</time_frame>
        <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibody Titers</title>
          <description>Titers are given as Geometric Mean Titers (GMTs) expressed as EL.U/mL.</description>
          <population>Analysis was performed on a subset from the ATP cohort for analysis of immunogenicity, in subjects for which a blood sample was taken at Month 2 and were seronegative for the corresponding HPV type before vaccination, i.e. with antibody titers below 8 EL.U/mL for anti-HPV-16 antibodies and below 7 EL.U/mL for anti-HPV-18 antibodies.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 GMTs (n= 105, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5215.2" lower_limit="4598.2" upper_limit="5915.0"/>
                    <measurement group_id="O2" value="4967.2" lower_limit="4142.5" upper_limit="5956.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 GMTs (n= 112, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4496.8" lower_limit="3899.4" upper_limit="5185.8"/>
                    <measurement group_id="O2" value="4266.5" lower_limit="3562.9" upper_limit="5109.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include injection site pain, redness and swelling. Data are presented across doses.</description>
        <time_frame>During the 7-day period (Day 0-6) following vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include injection site pain, redness and swelling. Data are presented across doses.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="250"/>
                    <measurement group_id="O3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="137"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, rash, temperature [axillary route, greater than or equal to 37.5 degree Celsius (°C)] and urticaria.</description>
        <time_frame>During the 7-day period following vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, rash, temperature [axillary route, greater than or equal to 37.5 degree Celsius (°C)] and urticaria.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Medically Significant Conditions</title>
        <description>Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
        <time_frame>Throughout the active phase of the study (up to Month 7)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Medically Significant Conditions</title>
          <description>Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Medically Significant Conditions</title>
        <description>Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
        <time_frame>Throughout the safety follow-up (from Month 7 up to Month 12)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Medically Significant Conditions</title>
          <description>Medically significant conditions include adverse events (AEs) prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
        <description>Unsolicited adverse events include any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 30-day period following any vaccination</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
          <description>Unsolicited adverse events include any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Throughout the study (up to Month 12)</time_frame>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix™ &amp; Twinrix™ Group</title>
            <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O2">
            <title>Cervarix™ Group</title>
            <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
          </group>
          <group group_id="O3">
            <title>Twinrix™ Group</title>
            <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="270"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 0 up to Month 12</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cervarix™ &amp; Twinrix™ Group</title>
          <description>Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A &amp; Hepatitis B (HAB) vaccine (Months 0, 1 &amp; 6).</description>
        </group>
        <group group_id="E2">
          <title>Cervarix™ Group</title>
          <description>Subjects received 3 doses of HPV vaccine (Months 0, 1 &amp; 6).</description>
        </group>
        <group group_id="E3">
          <title>Twinrix™ Group</title>
          <description>Subjects received 3 doses of HAB vaccine (Months 0, 1 &amp; 6).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Venous injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="251" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="202" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at injection site</sub_title>
                <counts group_id="E1" subjects_affected="251" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="202" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Redness at injection site</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Swelling at injection site</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="270"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

